Health organisations are urging Andy Burnham to scrap a UK-US trade deal on medicines, warning it could lead to 229,000 excess deaths by 2036. Critics argue the agreement prioritises pharmaceutical profits over patient care, potentially diverting £45 billion from essential NHS services. This financial strain could exacerbate existing issues within the NHS, where patients are already facing long wait times and inadequate care.
The deal, signed last December, has been defended by ministers as a means to enhance British drug exports and improve patient access to life-saving medications. However, the analysis suggests that the costs associated with the deal will significantly impact NHS funding, leading to a detrimental effect on public health.
Burnham, who is expected to become the next Labour leader and Prime Minister, faces pressure to reverse this agreement. Health groups argue that maintaining the deal would be a betrayal of the NHS and its patients, calling for a decisive shift towards prioritising public health over corporate interests.
As Burnham prepares for leadership, his decisions on this matter could shape the future of the NHS and its ability to provide care. The urgency of this situation highlights the need for a commitment to restoring funding and trust in the health service, ensuring it remains a public priority rather than a profit-driven enterprise.
Source: The Guardian
